Management & Board

Management & Board Prof. Jian Sheg Sun serves as acting CEO and CSO of DNA Therapeutics during the initial phase of the company’s corporate development. He will focus on defining strategy and road map, as well as on establishing networks and on implementing scientific and technical supervision to steer the company’s development. He will also be dedicated to corporate management and development, contacts with institutional, public and private investors, business networking, as well as to respond to the calls for project from French, European and US public institutions for subsidies and networking. The founders are very much aware that they are mainly coming from the scientific medical community and need to supplement this by attracting people with very strong managerial, business development and financial skills, as well as experts in R&D, preclinical and clinical development, regulatory affaires They have already been in touch with experienced professionals, and benefited from their valuable support and coaching. A full corporate management team will be gradually built up along with the generation of additional compelling data which will secure the clinical development plan, and in any case prior to the closing of the 2nd round of equity investment. The founders and the management believe that DNA Therapeutics is originally positioned in the emerging molecular radiotherapy and molecular chemotherapy fields to develop novel, life-saving therapeutic products for cancer treatment. The Board of Directors consists of the following individuals with extensive experience in biotechnology, in pharmaceutical industry, in drug development and start-up ventures:Chairman of the board: Dr. Georges A. Marcel, M. D. & Ph. D.. Founder and chairman of the Scientific Advisory Board of HealthValue Ltd., specialized in biotechnology competitive intelligence. Previously, He was Chairman and CEO of TMC Development, a biopharmaceutical consulting firm based in Paris, essentially involved with US Biotech. Clients are Biotechnology corporations and Institutional investors. Prior to this, he held a number of senior executive positions in pharmaceutical industry, including President & CEO of Amgen’ French subsidiary that he created from nil the entire French operation and obtained approval and pricing for Neupogen in record time; VP of marketing worldwide for Rhône-Poulenc Santé, VP of preclinical & clinical drug development worldwide, head of R&D executive committee for Roussel-Uclaf; CEO of Laboratores Roussel; VP director of marketing for Hoechst. He was also a member of the Gene Therapy Advisory Committee at the French Medicines Agency. He was a board director of Hybridon Inc. , and is currently a board director and member of the Audit Committee of Pharmos Inc. Mr. Bernard Davitian, MBA, is currently EVP & CFO of Fovea Pharmaceuticals, a biotech company specialized in ophthalmology. Mr. Davitian has about 20 years of business and corporate finance experience in the biotech industry, marked by many fund raising and M&A closed. He is the former CEO of Neurotech, a biopharmaceutical company that he refocused on ophthalmology. He led Neurotech’s Series C round and relocated the Company fully to the US near Boston. Mr. Davitian was previously EVP & CFO of Transgene, a gene therapy company that he took public on the Nasdaq and Euronext in 1998. From 1986 to 1994, Mr. Davitian started his career in the biotech sector by serving in various capacities at Pasteur Mérieux, a world leader in vaccines, including that of Corporate CFO from 1990 to 1994. He was involved in a number of global strategic operations, including a key role in the acquisition of Connaught Laboratories in 1989. Mr. Davitian holds an MBA from the Graduate School of Business of Lyon and an Executive MBA from the Wharton School of Business at the University of Pennsylvania.

Карта сайта

Информационный сайт